Diabetes News

Preadmission metformin use was associated with reduced 30-day mortality among medical and surgical intensive care patients with type 2 diabetes (Critical Care)

http://www.scottishmedicines.org.uk/SMC_Advice/Advice/903_13_lixisenatide_Lyxumia/lixisenatide_Lyxumia

Empagliflozin provides a tolerable and efficacious strategy to reduce HbA1c in patients with type 2 diabetes who had not previously received drug treatment (The Lancet)

Presently, choosing between a SGLT2 inhibitor and a DPP4 inhibitor to manage hyperglycaemia in type 2 diabetes is difficult: each pharmacological class has advantages and disadvantages. The clinical results of large, long-term, prospective placebo-controlled trials assessing cardiovascular outcomes, presently in progress with DPP4 inhibitors and SGLT2 inhibitors will help guide clinicians further (The Lancet)

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo (New England Journal of Medicine)

DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes (New England Journal of Medicine)

SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments (AstraZeneca)

Video presentation (PeerVoice)

If our findings reported here are reproduced in clinical studies, our study may have important clinical implications in the way these drugs should be administered in cardiac dysfunction (Journal of Diabetes Research)

This is the first study to report a significant association between statin use and diminished amputation risk among patients with diabetes (Journal of Vascular Surgery)

Empagliflozin 10 and 25 mg for 24 weeks as add-on to metformin plus sulfonylurea improved glycemic control, weight, and systolic blood pressure and were well tolerated (Diabetes Care)

The observed 16.6% reduction in glycemia will prove clinically relevant if shown to translate to a similar reduction in both HbA1c concentrations and risk of diabetes-related complications in longer trials (PLoS ONE)

In general, treatment with AFREZZA (an inhalation Powder) was well-tolerated over 24 weeks by subjects with type 1 diabetes. The incidence of serious adverse events related to study drug was similar in the AFREZZA-Gen2 (2.3%), AFREZZA-MedTone (2.9%) and insulin aspart (1.8%) groups. (MannKind Corporation)

Compared with equal-dosage metformin monotherapy, the initial combination of metformin and DPP-IV inhibitors were more effective in glycemic control without additional risk of adverse events, therefore it can be considered as a beneficial therapeutic regimen for drug-naïve type 2 diabetes patients (Diabetes, Obesity and Metabolism)

In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo. These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients (The Lancet)

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus (All Wales Medicines Strategy Group)

Endocrinologic and Metabolic Drugs Advisory Committee will discuss new drug application (NDA) 202293 dapagliflozin (FDA

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Vipidia, 6.25 mg, 12.5 mg and 25 mg, film-coated tablet intended for the treatment of type 2 diabetes mellitus (European Medicines Agency)

No new concerns for GLP-1 therapies identified on the basis of available evidence (European Medicines Agency)

Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D (Diabetes Care)